Genetic Diversity of Sickle Cell Disease in Nigeria: Implication for Emerging Gene Therapy and Health Equity
Article Information
Publication Timeline
- Received18 August 2025
- Accepted19 September 2025
- Published
Abstract
Sickle cell disease (SCD) remains one of the most significant monogenic disorders globally, with Nigeria bearing the highest prevalence, accounting for nearly 50% of the world’s annual births with SCD. The genetic landscape of SCD in Nigeria is remarkably heterogeneous, characterized by diverse β-globin haplotypes, varying allele frequencies, and multiple genetic modifiers influencing clinical outcomes. This review synthesizes current knowledge on the molecular and haplotypic diversity of SCD in Nigeria and highlights its implications for disease phenotype, prognosis, and therapeutic response. We critically evaluate the current management landscape, including hydroxyurea therapy, transfusion programs, and newborn screening efforts, while identifying barriers to equitable access. Furthermore, we examine emerging gene therapy approaches—lentiviral gene addition, CRISPR-Cas9 gene editing, and HbF reactivation—and assess their relevance to Nigeria’s unique genotype distribution and healthcare infrastructure. Finally, we discuss health equity, policy priorities, and capacity-building strategies necessary to ensure broad, affordable access to curative therapies. Our review underscores the dual imperative of scientific innovation and health equity to transform SCD outcomes in Nigeria.
Keywords
β-Globin HaplotypesGenomic MedicineGenetic DiversityGene TherapyHealth EquityPrecision MedicineNigeriaSickle Cell DiseaseHow to Cite
Obaze, G. E., Chukwu, O. J., Idogho, O. P., Olanrewaju, A. R., Mene, Y. V., Okei, N. C., Ayemoba, G. A., Olatokun, T. P., Tijani, F. T., & Ali, A. S. (2025). Genetic Diversity of Sickle Cell Disease in Nigeria: Implication for Emerging Gene Therapy and Health Equity. International Journal of Medical and All Body Health Research, 6(4), 38-48. https://doi.org/10.54660/IJMBHR.2025.6.4.38-48
Obaze, Godfrey Eshikhena, et al. "Genetic Diversity of Sickle Cell Disease in Nigeria: Implication for Emerging Gene Therapy and Health Equity." International Journal of Medical and All Body Health Research, vol. 6, no. 4, 2025, pp. 38-48. https://doi.org/10.54660/IJMBHR.2025.6.4.38-48.
Obaze, G. E., Chukwu, O. J., Idogho, O. P., Olanrewaju, A. R., Mene, Y. V., Okei, N. C., Ayemoba, G. A., Olatokun, T. P., Tijani, F. T. and Ali, A. S. (2025) 'Genetic Diversity of Sickle Cell Disease in Nigeria: Implication for Emerging Gene Therapy and Health Equity', International Journal of Medical and All Body Health Research, 6(4), pp. 38-48. doi: 10.54660/IJMBHR.2025.6.4.38-48.
Obaze GE, Chukwu OJ, Idogho OP, Olanrewaju AR, Mene YV, Okei NC, et al. Genetic Diversity of Sickle Cell Disease in Nigeria: Implication for Emerging Gene Therapy and Health Equity. International Journal of Medical and All Body Health Research. 2025;6(4):38-48. doi:10.54660/IJMBHR.2025.6.4.38-48
Similar Articles
- Challenges of Applying Evidence -Based Practice in Nursing: Subject Review Vol 6, Issue 4 (2025)
- IoT Device Security in Modern Healthcare: Addressing Cyber Threats to Connected Medical Equipment Vol 6, Issue 4 (2025)
- Closing the Funding Gap: Accelerating Biochemical Research to Transform Postpartum Depression Care Vol 6, Issue 4 (2025)
- Prevalence and Associated Risk Factors of Obesity from six to 16-year-old Children Vol 6, Issue 4 (2025)
- Indoor Air Microbiome in Crowded Public Spaces: A Study of Classrooms and Public Transport Hubs in Owerri, Imo State, Nigeria Vol 6, Issue 4 (2025)
Find this Article on
Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASEA newly published article may take a few days to appear on these services.